Physician profile
Jawed Hussain
NPI 1578669933
$315.67
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $11.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $66.58 | 2019 | |
| Nevro Corp. | $58.87 | 2019 | |
| Collegium Pharmaceutical, INC. | $48.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.33 | 2019 | |
| Tersera Therapeutics LLC | $30.50 | 2019 | |
| Shionogi INC | $13.61 | 2019 | |
| Amgen INC. | $13.37 | 2019 | |
| Pfizer INC. | $12.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.77 | 2019 | |
| Zyla Life Sciences, INC. | $11.76 | 2020 | |
| Daiichi Sankyo INC. | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawed Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.